A Clinical Trial to evaluate the Pharmacokinetics and safety of CKD-344
A Phase 1 Clinical Trial to evaluate the safety and pharmacokinetics in healthy adult volunteers after administration of CKD-344.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
60
NOAC(Factor Xa inhibitor)
NOAC(Factor Xa inhibitor)
H+ Yangji Hospital
Seoul, South Korea
RECRUITINGAUCt(Area Under Curve last) of CKD-344
Area under the plasma concentration time curve of CKD-344, from time zero up to the last measurable concentration.
Time frame: predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours post-dose
Cmax
The maximum concentration observed of CKD-344 over blood sampling time.
Time frame: predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours post-dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.